$24.7 M

ABIO Mkt cap, 23-Sept-2020
ARCA biopharma Net income (Q2, 2020)-1.3 M
ARCA biopharma EBIT (Q2, 2020)-1.3 M
ARCA biopharma Cash, 30-Jun-202011 M
ARCA biopharma EV38.6 M

ARCA biopharma Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

R&D expense

2.3m1.1m2.9m5.6m7.1m12.3m14.1m4.2m1.8m

General and administrative expense

5.0m3.2m4.0m4.1m4.4m4.3m4.6m3.9m4.0m

Operating expense total

7.4m4.3m6.9m9.7m11.5m16.6m18.7m8.1m5.8m

EBIT

(7.4m)(4.3m)(6.9m)(9.7m)(11.5m)(16.6m)(18.7m)(8.1m)(5.8m)

Interest expense

5.0k3.0k

Interest income

2.0k2.0k5.0k7.0k14.0k169.0k167.0k162.0k172.0k

Pre tax profit

(5.4m)(4.3m)(6.9m)(18.6m)(8.0m)(5.6m)

Income tax expense

(61.0k)(31.0k)(167.0k)

Net Income

(5.4m)(4.3m)(6.9m)(9.7m)(11.4m)(16.4m)(18.5m)(7.9m)(5.5m)

ARCA biopharma Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

7.5m5.7m4.2m3.2m3.1m3.5m20.4m18.6m21.2m19.4m17.2m12.2m44.1m41.5m29.7m14.4m8.1m6.2m9.1m8.1m12.1m9.6m8.1m8.0m10.0m9.6m6.7m11.0m

Prepaid Expenses

364.0k340.0k475.0k408.0k184.0k456.0k284.0k379.0k599.0k303.0k216.0k490.0k241.0k205.0k391.0k377.0k320.0k643.0k648.0k425.0k631.0k375.0k336.0k513.0k357.0k259.0k

Current Assets

7.8m6.1m4.7m3.6m3.3m4.0m20.7m19.0m21.8m19.7m17.5m12.7m44.3m41.7m31.0m26.7m23.8m19.9m16.7m16.4m12.7m10.0m8.4m8.5m10.3m9.9m7.4m11.6m

PP&E

490.0k166.0k52.0k43.0k33.0k22.0k21.0k27.0k26.0k29.0k26.0k34.0k34.0k31.0k24.0k76.0k69.0k59.0k54.0k48.0k37.0k33.0k29.0k19.0k13.0k10.0k10.0k12.0k

Total Assets

8.6m6.5m5.0m3.8m3.5m4.1m20.8m19.1m22.7m20.5m18.0m13.3m45.1m42.4m36.9m32.6m28.7m20.6m17.3m16.9m12.8m10.1m8.4m8.6m10.4m9.9m7.5m11.6m

Accounts Payable

517.0k284.0k126.0k227.0k119.0k377.0k387.0k447.0k552.0k725.0k365.0k651.0k714.0k647.0k744.0k760.0k1.1m980.0k1.1m1.2m772.0k406.0k217.0k260.0k254.0k135.0k167.0k576.0k

Short-term debt

50.0m25.0m

Current Liabilities

1.0m661.0k594.0k529.0k286.0k828.0k750.0k769.0k1.1m1.2m838.0k1.1m1.4m1.3m2.3m1.7m2.2m2.5m2.5m2.5m1.7m1.1m978.0k1.3m1.2m1.2m1.2m1.3m

Total Debt

50.0m25.0m

Total Liabilities

1.0m686.0k602.0k529.0k286.0k828.0k750.0k769.0k1.1m1.2m841.0k1.1m1.4m1.3m1.7m2.2m2.6m2.5m2.6m1.7m1.1m982.0k

Common Stock

11.0k11.0k12.0k12.0k15.0k3.0k10.0k13.0k21.0k21.0k21.0k21.0k63.0k9.0k9.0k9.0k9.0k9.0k10.0k12.0k14.0k14.0k14.0k1.0k1.0k2.0k2.0k2.0k

Additional Paid-in Capital

67.8m67.8m69.4m69.5m70.3m72.4m90.3m90.3m98.8m99.0m99.2m99.5m133.8m134.0m134.3m134.5m134.7m134.9m137.1m141.1m144.8m144.8m144.9m147.9m151.2m152.0m152.0m157.3m

Retained Earnings

(60.2m)(62.0m)(65.1m)(66.2m)(67.2m)(69.1m)(70.3m)(72.0m)(77.3m)(79.7m)(82.0m)(87.4m)(90.1m)(92.9m)(99.7m)(103.6m)(108.3m)(116.8m)(122.4m)(126.8m)(133.7m)(135.9m)(137.4m)(140.6m)(142.0m)(143.2m)(145.7m)(147.0m)

Total Equity

7.5m5.8m4.4m3.3m3.2m3.3m20.0m18.4m21.5m19.3m17.2m12.1m43.8m41.1m34.6m30.9m26.5m18.0m14.7m14.4m11.1m9.0m7.5m7.3m9.2m8.8m6.3m10.3m

Financial Leverage

1.1 x1.1 x1.1 x1.2 x1.1 x1.3 x1 x1 x1.1 x1.1 x1 x1.1 x1 x1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.2 x1.2 x1.1 x1.1 x1.2 x1.1 x1.1 x1.2 x1.1 x

ARCA biopharma Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(1.9m)(3.7m)(1.4m)(2.6m)(3.5m)(1.1m)(2.3m)(4.0m)(2.4m)(4.8m)(7.1m)(2.7m)(5.5m)(8.3m)(3.6m)(7.5m)(12.2m)(4.3m)(9.9m)(14.3m)(2.7m)(4.9m)(6.4m)(1.7m)(3.1m)(4.3m)(1.3m)(2.6m)

Depreciation and Amortization

195.0k518.0k14.0k24.0m34.0k10.0k19.0k24.0k3.0k5.0k8.0k4.0k9.0k14.0k62.0k126.0k224.0k97.0k193.0k290.0k6.0k11.0k17.0k5.0k11.0k16.0k3.0k4.0k

Accounts Payable

129.0k(104.0k)(134.0k)(34.0k)(141.0k)312.0k322.0k382.0k(45.0k)128.0k(232.0k)(144.0k)(198.0k)(167.0k)380.0k391.0k648.0k(234.0k)(141.0k)29.0k(14.0k)(217.0k)(405.0k)(2.0k)(13.0k)(95.0k)(293.0k)(103.0k)

Cash From Operating Activities

(4.0m)(5.7m)(1.7m)(2.6m)(3.4m)(764.0k)(1.7m)(3.4m)(3.7m)(5.4m)(7.5m)(3.1m)(5.5m)(7.9m)(3.9m)(7.4m)(11.1m)(4.3m)(9.3m)(13.3m)(3.1m)(5.3m)(6.9m)(1.6m)(2.8m)(3.6m)(1.7m)(2.7m)

Purchases of PP&E

(1.0k)(1.0k)(1.0k)(1.0k)(9.0k)(17.0k)(28.0k)(5.0k)(5.0k)(2.0k)(7.0k)(9.0k)(1.0k)(2.0k)(8.0k)(2.0k)(2.0k)(1.0k)(1.0k)(4.0k)(2.0k)(3.0k)(6.0k)

Cash From Investing Activities

2.0m2.0m(1.0k)(1.0k)(9.0k)(17.0k)(28.0k)(5.0k)(5.0k)(2.0k)(7.0k)(9.0k)(5.2m)(17.0m)(19.6m)3.0m9.1m8.2m3.0m3.0m3.0m(2.0k)(3.0k)(6.0k)

Short-term Borrowings

(55.0k)(138.0k)(193.0k)(170.0k)(256.0k)(206.0k)(206.0k)(116.0k)(231.0k)(135.0k)

Cash From Financing Activities

2.5m2.4m(60.0k)(127.0k)547.0k1.4m19.2m19.2m8.1m8.1m8.0m(55.0k)34.3m34.1m105.0k1.9m5.8m3.4m3.2m3.2m3.0m6.1m6.7m5.4m

Net Change in Cash

438.0k(1.3m)(1.7m)(2.8m)(2.9m)617.0k17.5m15.7m4.4m2.6m493.0k(3.2m)28.7m26.1m(9.1m)(24.4m)(30.7m)(1.2m)1.7m741.0k3.4m933.0k(646.0k)1.4m3.4m3.0m(1.7m)2.7m

Interest Paid

2.0k4.0k2.0k3.0k1.0k3.0k3.0k1.0k2.0k3.0k1.0k3.0k4.0k4.0k6.0k6.0k6.0k3.0k6.0k4.0k

ARCA biopharma Ratios

USDQ2, 2011

Financial Leverage

1.1 x